Public Health Research Institute Center
UMDNJ - New Jersey Medical School
225 Warren Street
Newark, New Jersey 07103
Phone: (973) 854-3360
Dr. Drlica's laboratory focuses on fluoroquinolone action and resistance with M. tuberculosis and other bacteria. The fluoroquinolones trap DNA gyrase on bacterial DNA as ternary complexes that rapidly block DNA replication. It is widely believed that complex formation and rapid inhibition of replication cause cell death. However, the Drlica group recently showed that quinolone lethality is not diminished by blockage of replication by other means. In seeking another explanation for rapid cell death they found that it correlates with bacterial chromosome fragmentation. They are seeking to understand how fragmentation occurs in non-growing cells with the aim of developing new anti-tuberculosis fluoroquinolones. They are particularly encouraged by the unusual ability of moxifloxacin to kill M. tuberculosis in the absence of protein synthesis, and they developed an in vitro model for mycobacterial growth arrest using nitric oxide. Current work focuses on modeling quinolone-gyrase-DNA complexes and understanding the role of reactive oxygen species in quinolone-mediated cell death.
Work on resistance has focused on slowing the enrichment and amplification of bacterial subpopulations that are resistant. Early work showed that resistant bacterial mutants are selectively enriched when drug concentrations in agar plates fall inside a particular range (mutant selection window). That observation led to the mutant selection window hypothesis, which has now been tested with fluctuating drug concentrations in vitro and in an animal model with Staphylococcus aureus. It has also passed a small clinical test in which S. aureus resistance developed at the same time susceptible populations were eradicated. The hypothesis explains in part how traditional antimicrobial dosing strategies lead to resistance and suggests ways to severely restrict the acquisition of resistance. The hypothesis has been applied to the design of new fluoroquinolone-like compounds and the selection of mutants generated during treatment. The Drlica group hopes to be able to predict which antibiotic regimens are least likely to enrich mutants prior to widespread clinical use. Persons interested in selection window publications are referred to MSW papers
Other aspects of the work focus on understanding bacterial stress responses. Here the goal is to identify genes that protect from antimicrobial stress so small-molecule inhibitors can be identified that will enhance the lethal activity of many antimicrobials simultaneously.
Wu X, Wang X, Drlica K, Zhao X (2011) A toxin-antitoxin module in Bacillus subtilis can both mitigate and amplify effects of lethal stress. PLoS One 6: e23909. PMI: 21897862
Marks KR, Malik M, Mustaev A, Hiasa H, Drlica K, Kerns RJ (2011) Synthesis and evaluation of 1-cyclopropyl-2-thioalkyl-8-methoxy fluoroquinolones. Bioorg Med Chem Lett 21: 4585-4588. PMI: 21705218
Malik M, Marks KR, Mustaev A, Zhao X, Chavda K, Kerns RJ, Drlica K (2011) Fluoroquinolone and quinazolinedione activities against wild-type and gyrase mutant strains of Mycobacterium smegmatis. Antimicrob Agents Chemother 55: 2335-2343. PMI: 21383100
Liang B, Bai N, Cai Y, Wang R, Drlica K, Zhao X (2011) Mutant prevention concentration-based pharmacokinetic/pharmacodynamic indices as dosing targets for suppressing the enrichment of levofloxacin-resistant subpopulations of Staphylococcus aureus. Antimicrob Agents Chemother 55: 2409-2412. PMI: 21343454
Wang X, Zhao X, Malik M, Drlica K (2010) Contribution of reactive oxygen species to pathways of quinolone-mediated bacterial cell death. J Antimicrob Chemother 65: 520-524. PMI: 20067982
Oppegard LM, Streck KR, Rosen JD, Schwanz HA, Drlica K, Kerns RJ, Hiasa H (2010) Comparison of in vitro activities of fluoroquinolone-like 2,4- and 1,3-diones. Antimicrob Agents Chemother 54: 3011-3014. PMI: 20404126
Malik M, Marks KR, Schwanz HA, German N, Drlica K, Kerns RJ (2010) Effect of N-1/c-8 ring fusion and C-7 ring structure on fluoroquinolone lethality. Antimicrob Agents Chemother 54: 5214-5221. PMI: 20855738
Malik M, Hoatam G, Chavda K, Kerns RJ, Drlica K (2010) Novel approach for comparing the abilities of quinolones to restrict the emergence of resistant mutants during quinolone exposure. Antimicrob Agents Chemother 54: 149-156. PMI: 19805561
Han X, Dorsey-Oresto A, Malik M, Wang JY, Drlica K, Zhao X, Lu T (2010) Escherichia coli genes that reduce the lethal effects of stress. BMC Microbiol 10: 35. PMI: 20128927
Malik M, Capecci J, Drlica K (2009) Lon protease is essential for paradoxical survival of Escherichia coli exposed to high concentrations of quinolone. Antimicrob Agents Chemother 53: 3103-3105. PMI: 19414573
Hussain S, Malik M, Shi L, Gennaro ML, Drlica K (2009) In vitro model of mycobacterial growth arrest using nitric oxide with limited air. Antimicrob Agents Chemother 53: 157-161. PMI: 18955516
Drlica K, Hiasa H, Kerns R, Malik M, Mustaev A, Zhao X (2009) Quinolones: action and resistance updated. Curr Top Med Chem 9: 981-998. PMI: 19747119
Burger RM, Drlica K (2009) Superoxide protects Escherichia coli from bleomycin mediated lethality. J Inorg Biochem 103: 1273-1277. PMI: 19679357
Zhao X, Drlica K (2008) A unified anti-mutant dosing strategy. J Antimicrob Chemother 62: 434-436. PMI: 18544596
Usongo V, Nolent F, Sanscartier P, Tanguay C, Broccoli S, Baaklini I, Drlica K, Drolet M (2008) Depletion of RNase HI activity in Escherichia coli lacking DNA topoisomerase I leads to defects in DNA supercoiling and segregation. Mol Microbiol 69: 968-981. PMI: 18554330
German N, Malik M, Rosen JD, Drlica K, Kerns RJ (2008) Use of gyrase resistance mutants to guide selection of 8-methoxy-quinazoline-2,4-diones. Antimicrob Agents Chemother 52: 3915-3921. PMI: 18765690
Drlica K, Zhao X, Kreiswirth B (2008) Minimising moxifloxacin resistance with tuberculosis. Lancet Infect Dis 8: 273-275. PMI: 18471768
Drlica K, Malik M, Kerns RJ, Zhao X (2008) Quinolone-mediated bacterial death. Antimicrob Agents Chemother 52: 385-392. PMI: 17724149
Baaklini I, Usongo V, Nolent F, Sanscartier P, Hraiky C, Drlica K, Drolet M (2008) Hypernegative supercoiling inhibits growth by causing RNA degradation. J Bacteriol 190: 7346-7356. PMI: 18790862
Ye F, Brauer T, Niehus E, Drlica K, Josenhans C, Suerbaum S (2007) Flagellar and global gene regulation in Helicobacter pylori modulated by changes in DNA supercoiling. Int J Med Microbiol 297: 65-81. PMI: 17276136
Quinn B, Hussain S, Malik M, Drlica K, Zhao X (2007) Daptomycin inoculum effects and mutant prevention concentration with Staphylococcus aureus. J Antimicrob Chemother 60: 1380-1383. PMI: 17905797
Malik M, Hussain S, Drlica K (2007) Effect of anaerobic growth on quinolone lethality with Escherichia coli. Antimicrob Agents Chemother 51: 28-34. PMI: 17043118
Drlica K, Zhao X (2007) Mutant selection window hypothesis updated. Clin Infect Dis 44: 681-688. PMI: 17278059
Zhao X, Quinn B, Kerns R, Drlica K (2006) Bactericidal activity and target preference of a piperazinyl-cross-linked ciprofloxacin dimer with Staphylococcus aureus and Escherichia coli. J Antimicrob Chemother 58: 1283-1286. PMI: 17003060
Zhao X, Malik M, Chan N, Drlica-Wagner A, Wang JY, Li X, Drlica K (2006) Lethal action of quinolones against a temperature-sensitive dnaB replication mutant of Escherichia coli. Antimicrob Agents Chemother 50: 362-364. PMI: 16377712
Singh A, Singh Y, Pine R, Shi L, Chandra R, Drlica K (2006) Protein kinase I of Mycobacterium tuberculosis: cellular localization and expression during infection of macrophage-like cells. Tuberculosis (Edinb) 86: 28-33. PMI: 16256441
Malik M, Zhao X, Drlica K (2006) Lethal fragmentation of bacterial chromosomes mediated by DNA gyrase and quinolones. Mol Microbiol 61: 810-825. PMI: 16803589
Malik M, Drlica K (2006) Moxifloxacin lethality against Mycobacterium tuberculosis in the presence and absence of chloramphenicol. Antimicrob Agents Chemother 50: 2842-2844. PMI: 16870782
Hansen GT, Zhao X, Drlica K, Blondeau JM (2006) Mutant prevention concentration for ciprofloxacin and levofloxacin with Pseudomonas aeruginosa. Int J Antimicrob Agents 27: 120-124. PMI: 16426820
Drlica K, Zhao X, Blondeau JM, Hesje C (2006) Low correlation between MIC and mutant prevention concentration. Antimicrob Agents Chemother 50: 403-404. PMI: 16377725
Cui J, Liu Y, Wang R, Tong W, Drlica K, Zhao X (2006) The mutant selection window in rabbits infected with Staphylococcus aureus. J Infect Dis 194: 1601-1608. PMI: 17083047
Wehbeh W, Rojas-Diaz R, Li X, Mariano N, Grenner L, Segal-Maurer S, Tommasulo B, Drlica K, Urban C, Rahal JJ (2005) Fluoroquinolone-resistant Streptococcus agalactiae: epidemiology and mechanism of resistance. Antimicrob Agents Chemother 49: 2495-2497. PMI: 15917553
Malik M, Lu T, Zhao X, Singh A, Hattan CM, Domagala J, Kerns R, Drlica K (2005) Lethality of quinolones against Mycobacterium smegmatis in the presence or absence of chloramphenicol. Antimicrob Agents Chemother 49: 2008-2014. PMI: 15855526
Liu Y, Cui J, Wang R, Wang X, Drlica K, Zhao X (2005) Selection of rifampicin-resistant Staphylococcus aureus during tuberculosis therapy: concurrent bacterial eradication and acquisition of resistance. J Antimicrob Chemother 56: 1172-1175. PMI: 16207765
Wang JY, Drlica K (2004) Computational identification of antisense oligonucleotides that rapidly hybridize to RNA. Oligonucleotides 14: 167-175. PMI: 15625912
Shopsin B, Zhao X, Kreiswirth BN, Tillotson GS, Drlica K (2004) Are the new quinolones appropriate treatment for community-acquired methicillin-resistant Staphylococcus aureus? Int J Antimicrob Agents 24: 32-34. PMI: 15225857
Metzler K, Hansen GM, Hedlin P, Harding E, Drlica K, Blondeau JM (2004) Comparison of minimal inhibitory and mutant prevention drug concentrations of 4 fluoroquinolones against clinical isolates of methicillin-susceptible and -resistant Staphylococcus aureus. Int J Antimicrob Agents 24: 161-167. PMI: 15288315
Li X, Mariano N, Rahal JJ, Urban CM, Drlica K (2004) Quinolone-resistant Haemophilus influenzae in a long-term-care facility: nucleotide sequence characterization of alterations in the genes encoding DNA gyrase and DNA topoisomerase IV. Antimicrob Agents Chemother 48: 3570-3572. PMI: 15328129
Li X, Mariano N, Rahal JJ, Urban CM, Drlica K (2004) Quinolone-resistant Haemophilus influenzae: determination of mutant selection window for ciprofloxacin, garenoxacin, levofloxacin, and moxifloxacin. Antimicrob Agents Chemother 48: 4460-4462. PMI: 15504883
Etienne M, Croisier D, Charles PE, Lequeu C, Piroth L, Portier H, Drlica K, Chavanet P (2004) Effect of low-level resistance on subsequent enrichment of fluoroquinolone-resistant Streptococcus pneumoniae in rabbits. J Infect Dis 190: 1472-1475. PMI: 15378440
Epstein BJ, Gums JG, Drlica K (2004) The changing face of antibiotic prescribing: the mutant selection window. Ann Pharmacother 38: 1675-1682. PMI: 15340128
Drlica K, Zhao X (2004) Is "dosing-to-cure" appropriate in the face of antimicrobial resistance? Reviews in Medical Microbiology 15: 73-80. PMI: 0
Zinner SH, Lubenko IY, Gilbert D, Simmons K, Zhao X, Drlica K, Firsov AA (2003) Emergence of resistant Streptococcus pneumoniae in an in vitro dynamic model that simulates moxifloxacin concentrations inside and outside the mutant selection window: related changes in susceptibility, resistance frequency and bacterial killing. J Antimicrob Chemother 52: 616-622. PMI: 12951352
Zhao X, Eisner W, Perl-Rosenthal N, Kreiswirth B, Drlica K (2003) Mutant prevention concentration of garenoxacin (BMS-284756) for ciprofloxacin-susceptible or -resistant Staphylococcus aureus. Antimicrob Agents Chemother 47: 1023-1027. PMI: 12604537
Wang JY, Drlica K (2003) Modeling hybridization kinetics. Math Biosci 183: 37-47. PMI: 12604134
Lu T, Zhao X, Li X, Hansen G, Blondeau J, Drlica K (2003) Effect of chloramphenicol, erythromycin, moxifloxacin, penicillin and tetracycline concentration on the recovery of resistant mutants of Mycobacterium smegmatis and Staphylococcus aureus. J Antimicrob Chemother 52: 61-64. PMI: 12805268
Lu T, Drlica K (2003) In vitro activity of C-8-methoxy fluoroquinolones against mycobacteria when combined with anti-tuberculosis agents. J Antimicrob Chemother 52: 1025-1028. PMI: 14613961
Hansen GT, Metzler K, Drlica K, Blondeau JM (2003) Mutant prevention concentration of gemifloxacin for clinical isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother 47: 440-441. PMI: 12499234
Firsov AA, Vostrov SN, Lubenko IY, Drlica K, Portnoy YA, Zinner SH (2003) In vitro pharmacodynamic evaluation of the mutant selection window hypothesis using four fluoroquinolones against Staphylococcus aureus. Antimicrob Agents Chemother 47: 1604-1613. PMI: 12709329
Drlica K, Zhao X (2003) Fluoroquinolone-resistant Streptococcus pneumoniae. Reviews in Medical Microbiology 14: 1-9. PMI: 0
Drlica K, Malik M (2003) Fluoroquinolones: action and resistance. Curr Top Med Chem 3: 249-282. PMI: 12570763
Drlica K (2003) The mutant selection window and antimicrobial resistance. J Antimicrob Chemother 52: 11-17. PMI: 12805267
Chopra P, Singh A, Koul A, Ramachandran S, Drlica K, Tyagi AK, Singh Y (2003) Cytotoxic activity of nucleoside diphosphate kinase secreted from Mycobacterium tuberculosis. Eur J Biochem 270: 625-634. PMI: 12581202
Zhao X, Drlica K (2002) Restricting the selection of antibiotic-resistant mutant bacteria: measurement and potential use of the mutant selection window. J Infect Dis 185: 561-565. PMI: 11865411
Tillotson GS, Zhao X, Drlica K (2002) Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. N Engl J Med 347: 65-67; author reply 65-67. PMI: 12102062
Li X, Zhao X, Drlica K (2002) Selection of Streptococcus pneumoniae mutants having reduced susceptibility to moxifloxacin and levofloxacin. Antimicrob Agents Chemother 46: 522-524. PMI: 11796368
Drlica K, Schmitz FJ (2002) Therapeutic options in an era of decreasing antimicrobial susceptibility. J Chemother 14 Suppl 2: 5-12. PMI: 12003139
Zhao X, Drlica K (2001) Restricting the selection of antibiotic-resistant mutants: a general strategy derived from fluoroquinolone studies. Clin Infect Dis 33 Suppl 3: S147-156. PMI: 11524712
Urban C, Rahman N, Zhao X, Mariano N, Segal-Maurer S, Drlica K, Rahal JJ (2001) Fluoroquinolone-resistant Streptococcus pneumoniae associated with levofloxacin therapy. J Infect Dis 184: 794-798. PMI: 11517444
Tillotson G, Zhao X, Drlica K (2001) Fluoroquinolones as pneumococcal therapy: closing the barn door before the horse escapes. Lancet Infect Dis 1: 145-146. PMI: 11871490
Lu T, Zhao X, Li X, Drlica-Wagner A, Wang JY, Domagala J, Drlica K (2001) Enhancement of fluoroquinolone activity by C-8 halogen and methoxy moieties: action against a gyrase resistance mutant of Mycobacterium smegmatis and a gyrase-topoisomerase IV double mutant of Staphylococcus aureus. Antimicrob Agents Chemother 45: 2703-2709. PMI: 11557458
Koul A, Choidas A, Tyagi AK, Drlica K, Singh Y, Ullrich A (2001) Serine/threonine protein kinases PknF and PknG of Mycobacterium tuberculosis: characterization and localization. Microbiology 147: 2307-2314. PMI: 11496007
Heddle JG, Lu T, Zhao X, Drlica K, Maxwell A (2001) gyrB-225, a mutation of DNA gyrase that compensates for topoisomerase I deficiency: investigation of its low activity and quinolone hypersensitivity. J Mol Biol 309: 1219-1231. PMI: 11399091
Friedman SM, Lu T, Drlica K (2001) Mutation in the DNA gyrase A Gene of Escherichia coli that expands the quinolone resistance-determining region. Antimicrob Agents Chemother 45: 2378-2380. PMI: 11451702
Drlica K (2001) Antibiotic resistance: can we beat the bugs? Drug Discov Today 6: 714-715. PMI: 11445459
Blondeau JM, Zhao X, Hansen G, Drlica K (2001) Mutant prevention concentrations of fluoroquinolones for clinical isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother 45: 433-438. PMI: 11158737
Drlica, K., Zhao, X., Malik, M., Salz, T., and Kerns, R. (in press)
Fluoroquinolone resistance: mechanisms, restrictive dosing, and anti-mutant screening strategies for new compounds.
In Antibiotic Discovery and Development, Michael J. Pucci and Thomas J. Dougherty, Eds., Springer-Verlag.
Drlica, K., and Bendich, A. (2009)
In Encyclopedia of Microbiology, M. Schaechter, Ed. p. 507-516.
Drlica, K., Zhao, X., and Malik, M. (2009)
In Encyclopedia of Microbiology, M. Schaechter, Ed. p. 707-716.
Drlica, K., Wang, J.-Y., Malik, M., Lu, T., Logan, C., Park, S., Li, X., Perlin, D., Zhao, X. (2008).
An anti-mutant approach for antimicrobial use.
In Antimicrobial Resistance and Implications for the 21st Century, I. Fong, K. Drlica, eds. Springer: New York. p. 371-400.
Wang. J.-Y. and Drlica, K. (2007)
Selection of Target Sites in RNA for Antisense Agents.
In Antisense Elements (Genetics) Research Focus, Ed.: A.G. Hernandez. Nova Science Publishers, Inc. p. 71-89.
Drlica, K., Lu, T., Malik, M., and Zhao, X. (2004).
Fluoroquinolones as antituberculosis agents.
In Tuberculosis, W. Rom and S. Garay, eds. pp. 791-807.
Drlica, K. and Hooper, D. (2003).
Mechanism of quinolone action.
In The Quinolones, D. Hooper, ed. American Soc. Microbiology: Washington, pp.19-40.
Drlica, K. and Zhao, X. (2003).
Controlling antibiotic resistance: strategies based on the mutant selection window.
In Re-emergence of established microbial pathogens in the 21st century, I.W. Fong and K. Drlica, eds., Kluwer Academic Plenum Publishers, pp. 295-331.
Drlica, K. and Gennaro, M. (2001).
In Encyclopedia of Genetics, S. Brenner and J. Miller, editors-in-chief, Academic Press pp. 1485-1490.
Drlica, K. and Bendich, A. (2000).
In Encyclopedia of Microbiology, J. Lederberg, ed. second edition; p. 808-821.
Drlica, K., Wu, E.-D., C.-R. Chen, J.-Y. Wang, Zhao, X., Xu, C., Qiu, L., Malik, M., Kayman, S., and Friedman, M. (1999).
Prokaryotic DNA topology.
In Prokaryotic Gene Expression (Frontiers in Molecular Biology); edited by S. Baumberg, ed. pp. 141-168.
Drlica, K. and Woldringh, C. (1998).
Chromosomal organization: nucleoids, chromosomal folding, and DNA topology.
In Bacterial Genomes: Physical Structure and Analysis, edited by F. de Bruijn, J. Lupski, and G. Weinstock. pp 12-22.
Drlica, K., Malik, M., Wang, J.-Y, Levitz, R., and R. Burger. (1996).
The fluoroquinolones as antituberculosis agents.
In Tuberculosis, edited by W. Rom and S. Garay; Little, Brown and Co, NY. 817-827.
Drlica, K. (1992).
The bacterial chromosome.
In Encyclopedia of Microbiology, edited by J. Lederberg 1: 517-527.
Drlica, K and Riley, M. (1990).
An historical introduction to the bacterial chromosome.
In The Bacterial Chromosome, K. Drlica and M. Riley, eds, American Society for Microbiology: Washington, D.C. pp. 3-13.
Drlica, K., Pruss, G., Burger, R. Franco, R., Hsieh, L., and Berger, B. (1990).
Roles of DNA topoisomerases in bacterial chromosome structure and function.
In The Bacterial Chromosome, K. Drlica and M. Riley, eds, American Society for Microbiology: Washington, D.C. pp. 195-204.
Drlica, K., Coughlin, S., and Gennaro, M. (1990).
Mode of action of quinolones: biochemical aspects.
In The New Generation of Quinolones, J. Domagala, C. Heifetz, and C. Siporin, eds., Marcel Dekker Press pp. 45-62.
Drlica, K. (1990).
Genetic Engineering: The Gene.
In Comprehensive Medicinal Chemistry, Volume 1; P.D. Kennewell, editor. Pergamon Press. p. 361-408.
Drlica, K. (1987).
In Escherichia coli and Salmonella typhimurium: Cellular and Molecular Biology, F. Neidhardt, ed. 91-103.
Drlica, K., and Zhao., X. (2008).
Mutant selection window hypothesis: a framework for anti-mutant dosing of antimicrobial agents.
In National Institute of Allergy and Infectious Diseases, NIH Volume 1, Frontiers in Research, V. Georgiev, Editor. Humana Press Inc., Totawa, NJ. pp 101-106.
Drlica, K. (1999).
Mechanisms of fluoroquinolone action and resistance.
In First International Moxifloxacin Symposium, Berlin, 1999; L. Mandell, Ed. pp 75-83.
Burger, R., and Drlica, K. (1996).
Bleomycin reaction pathways: kinetic approaches.
In DNA Cleavers and Chemotherapy of Cancer or Viral Diseases, edited by B. Meunier, Kluwer Academic Publishers, Dordrecht, pp 91-106.
Rouviere-Yaniv, J., Kiseleva, E., Almeida, A., and Drlica, K. (1992).
Protein HU and DNA supercoiling.
In Prokaryotic Structure and Function: A New Perspective, edited by. S. Mohan, C. Dow, and J. Cole. Soc. for General Microbiol. Symp. 47:414-438.
Hsieh, L.-S., Burger, R.M., and Drlica, K. (1990).
DNA topoisomerases and the bacterial chromosome.
In Structural and Organizational Aspects of Metabolic Regulation, UCLA Symposia on Molecular and Cellular Biology, New Series, Volume 134, P. Srere, M.E. Jones, and C. Mathews, eds., Alan R. Liss, Inc., New York, NY pp. 153-164.
Franco, R., T. Steck, S. Chevalier, and K. Drlica. (1987).
Bacterial topoisomerase mutations: effects on abundance of proteins and suppression of gyrB by rpoB.
In Mechanisms of DNA Replication and Recombination, UCLA Symposia on Molecular and Cellular Biology, New Series. 47: 533-541.
Drlica, K., G. J. Pruss, S. H. Manes, and S. G. Chevalier. (1986).
DNA topoisomerase mutations in bacteria.
In Bacterial Chromatin, C. Gualerzi, ed. Springer-Verlag. pp. 52-63.
Drlica, K. and A. Worcel. (1975).
Viscometric analysis of conformational transitions in the Escherichia coli chromosome.
DNA Replication: ICN-UCLA Symposium on Molecular Biology (F. Fox and P. Hanawalt, eds.). pp 138-158.
Drlica, K., and Perlin, D.S. (in press).
(FT Press: Science)
Drlica, K. (2003).
Understanding DNA: A Guide for the Curious.
(John Wiley & Sons, Fourth Edition)
Drlica, K. (1997).
Understanding DNA: A Guide for the Curious.
(John Wiley & Sons, Third Edition).
Drlica, K. (1996).
Double-Edged Sword: The Promises and Risks of the Genetic Revolution.
Addison-Wesley 242 pp. (revised paperback edition).
Drlica, K. (1994).
Double-Edged Sword: The Promises and Risks of the Genetic Revolution.
Addison-Wesley 242 pp.
Drlica, K. (1992).
Understanding DNA and Gene Cloning: A Guide for the Curious.
John Wiley & Sons, 2nd edition 240 pp. (edtions in English and German).
Drlica, K. (1984).
Understanding DNA and Gene Cloning: A Guide for the Curious.
John Wiley and Sons, Inc. 205 pp. (editions in English, Japanese, and Italian).
Fong, I.W. and Drlica, K. eds. (2008).
Antimicrobial Resistance and Implications for the 21st Century
Springer Science+Business Media, pp 407.
Fong, I.W., and Drlica, K. eds. (2003).
Re-emergence of established microbial pathogens in the 21st century.
Kluwer/Plenum Press, pp. 367.
Drlica, K. and Riley, M., eds. (1990).
The Bacterial Chromosome.
American Society of Microbiology: Washington 469 pp.
Other Sponsored Work
Wang, X. and Zhao, X. (2009).
Contribution of oxidative damage to antibiotic lethality.
Antimicrob. Agents Chemother. 53:1395-1402.
Wu, X., Wang, H., and Zhao, X. (2008).
Antimicrobial studies with the Pseudomonas aeruginosa two-allele library require caution.
Antimicrob. Agents Chemonther. 52: 3826-3827.
Zhao X. (2003).
Clarification of MPC and the mutant selection window concept.
J Antimicrob Chemother. 2003 Oct;52(4):731; author reply 732-3. Epub 2003 Sep 12.
Lu, T., Malik, M., and Drlica-Wagner, A. (2001).
Research Advances in Antimicrobial Agents & Chemother. 2001;2:29-42.
Wang, J.-Y. (1998).
Mathematical relationships among DNA supercoiling, cation concentration, and temperature for prokaryotic transcription.
Mathematical Biosciences. 1998;151:155-63.
Pruss, G. (1985).
DNA topoisomerase I mutants: increased heterogeneity in linking number and other replicon-dependent changes in DNA supercoiling.
J. Mol. Biol. 1985;185:51-63.